Syndax Pharmaceuticals Inc. (SNDX)
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals Q2 Earnings Call Highlights
Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Syndax Pharmaceuticals NASDAQ: SNDX used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell lung cancer and myelofibrosis.
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced
Syndax has transitioned into a two-product commercial oncology company with growing revenue and strong cash reserves. Revuforj and Niktimvo drive SNDX's revenue, with Q1 2026 net sales exceeding $100M and significant expansion potential in AML and chronic GVHD. Revuforj's broad FDA approval and post-transplant maintenance potential, alongside Niktimvo's unique mechanism, underpin a multi-billion dollar franchise opportunity.
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
